Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04021706 · ClinicalTrials.gov registry record · Phase 1
Effect of a Ghrelin Receptor Agonist on Muscle and Bone
A Phase 1 study, sponsored by Tufts University.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04021706: Completed Phase 1 study, sponsored by Tufts University.
NCT04021706 is a Phase 1 study that has completed, run by Tufts University. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04021706, a Phase 1 study, has completed, sponsored by Tufts University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Adults with low muscle mass also usually have low bone mass, making them vulnerable to falls, fractures and other injuries. This project will determine the effectiveness of treatment with a ghrelin receptor agonist in improving short term indicators of muscle and bone health in adults with low bone and muscle mass. The results of this trial will inform the design of a larger, definitive randomized trial designed to establish efficacy.
Primary Outcome
to be assessed by D3-creatine dilution
Interventions
- DRUG Placebo
- DRUG Anamorelin Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-12-05 |
| Est. Completion | 2023-01-26 |
| Phase | Phase 1 |
What the finished NCT04021706 record still lists
NCT04021706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04021706 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04021706 about?
NCT04021706 is a clinical study titled "Effect of a Ghrelin Receptor Agonist on Muscle and Bone". Adults with low muscle mass also usually have low bone mass, making them vulnerable to falls, fractures and other injuries. This project will determine the effectiveness of treatment with a ghrelin receptor agonist in improving short term indicators of muscle and bone health in adults with low bone ...
What is the current status of trial NCT04021706?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2019-12-05. Estimated completion is 2023-01-26.
What interventions are being tested in trial NCT04021706?
The interventions under investigation include: Placebo (DRUG), Anamorelin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04021706?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04021706's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI